Edgewise Therapeutics Statistics
Share Statistics
Edgewise Therapeutics has 94.69M shares outstanding. The number of shares has increased by 47.76% in one year.
| Shares Outstanding | 94.69M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.4% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 62.41M |
| Failed to Deliver (FTD) Shares | 2 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 7.29M, so 7.7% of the outstanding shares have been sold short.
| Short Interest | 7.29M |
| Short % of Shares Out | 7.7% |
| Short % of Float | 11.68% |
| Short Ratio (days to cover) | 7.56 |
Valuation Ratios
The PE ratio is -6.96 and the forward PE ratio is -19.03.
| PE Ratio | -6.96 |
| Forward PE | -19.03 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 2.19 |
| P/FCF Ratio | -7.14 |
| PEG Ratio | n/a |
Enterprise Valuation
Edgewise Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 19.5, with a Debt / Equity ratio of 0.
| Current Ratio | 19.5 |
| Quick Ratio | 19.5 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.31 |
| Cash Flow / Debt | -93.82 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.31% and return on capital (ROIC) is -35.27%.
| Return on Equity (ROE) | -0.31% |
| Return on Assets (ROA) | -0.29% |
| Return on Capital (ROIC) | -35.27% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -927.44K |
| Employee Count | 108 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 278.74% in the last 52 weeks. The beta is 0.15, so Edgewise Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.15 |
| 52-Week Price Change | 278.74% |
| 50-Day Moving Average | 32.59 |
| 200-Day Moving Average | 22.06 |
| Relative Strength Index (RSI) | 33.49 |
| Average Volume (20 Days) | 1.12M |
Income Statement
In the last 12 months, Edgewise Therapeutics had revenue of $0 and earned -$100.16M in profits. Earnings per share was $-1.57.
| Revenue | 0 |
| Gross Profit | -1.73M |
| Operating Income | -114.36M |
| Net Income | -100.16M |
| EBITDA | -112.81M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.57 |
Balance Sheet
The company has $86.10M in cash and $5.41M in debt, giving a net cash position of $80.68M.
| Cash & Cash Equivalents | 86.10M |
| Total Debt | 5.41M |
| Net Cash | 80.68M |
| Retained Earnings | -244.76M |
| Total Assets | 511.28M |
| Working Capital | 480.48M |
Cash Flow
In the last 12 months, operating cash flow was -$91.95M and capital expenditures -$5.75M, giving a free cash flow of -$97.69M.
| Operating Cash Flow | -91.95M |
| Capital Expenditures | -5.75M |
| Free Cash Flow | -97.69M |
| FCF Per Share | -1.53 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
EWTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -5.69% |
| FCF Yield | -3.74% |
Analyst Forecast
The average price target for EWTX is $45, which is 63% higher than the current price. The consensus rating is "Buy".
| Price Target | $45 |
| Price Target Difference | 63% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 70.63 |
| Piotroski F-Score | 3 |